Protective effect of fibronectin for endotoxin-induced liver injury after partial hepatectomy in rats.
BACKGROUND
Endotoxemia may occur after hepatectomy and become the cause of post-operative death. Fibronectins (Fns) are involved in a number of biological processes, such as cellular adhesion, motility, differentiation, apoptosis, hemostasis, wound healing, and ischemic injury. Studies were performed to determine whether Fn influences the survival rate of rats subjected to endotoxin-induced liver injury after partial hepatectomy.


METHODS
Lipopolysaccharide (LPS) was administered intravenously to male Sprague-Dawley rats within 48 h of 70% hepatectomy. Before LPS administration, plasma Fn or bovine serum albumin was given intravenously.


RESULTS
The survival rate of the Fn-treated group was markedly improved compared with that of the controls. Fn prevented increases in the concentrations of serum enzymes and total bilirubin related to liver injury. The levels of inflammatory cytokines, including tumor necrosis factor-alpha, interleukin-1beta, and cytokine-induced neutrophil chemoattractant, in serum and liver tissue, also were significantly lower in the Fn-treated group than in the control group. Furthermore, the degree of apoptosis and necrosis in remnant liver was significantly decreased in the Fn-treated rats compared with the controls.


CONCLUSIONS
These results indicate that Fn prevents endotoxin-induced liver injury after partial hepatectomy, at least in part through the inhibition of production of inflammatory cytokines, necrosis and apoptosis in the remaining liver.
Saito
Takamichi
T
Department of Surgery, KansaiMedical University, Moriguchi, Osaka, Japan.
Kwon
A-H O N
AH
Qiu
Zeyu
Z
Tsuchiya
Hideto
H
Tsuji
Katsushige
K
Kamiyama
Yasuo
Y
D000818:Animals; D017209:Apoptosis / Q000502:physiology; D016207:Cytokines / Q000032:analysis; D019446:Endotoxemia / Q000382:microbiology; D004731:Endotoxins / Q000009:adverse effects; D016326:Extracellular Matrix Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D005353:Fibronectins / Q000494:pharmacology / Q000627:therapeutic use*; D006498:Hepatectomy / Q000009:adverse effects*; D008070:Lipopolysaccharides / Q000009:adverse effects*; D008099:Liver / Q000098:blood supply / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D008107:Liver Diseases / Q000382:microbiology / Q000517:prevention & control*; D008297:Male; D023421:Models, Animal; D009336:Necrosis; D051381:Rats; D017207:Rats, Sprague-Dawley; D016019:Survival Analysis
D016207:Cytokines; D004731:Endotoxins; D016326:Extracellular Matrix Proteins; D005353:Fibronectins; D008070:Lipopolysaccharides